info@yvintelligence.com | +91-9458149365, +91-7666443274

Global Schizophrenia Drugs Market Forecast to 2030 - COVID-19 Impact and Analysis by Therapeutic Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others); by Treatment (Oral, Injectable); and Geography

  • Industry : Healthcare, Pharmaceutical, & Medical Devices
  • No. of Pages : 210
  • Report Code : YVHPMD10061

Schizophrenia Drugs Market Overview

Schizophrenia is a long-term mental disorder involving a breakdown in the relation between emotion, thought, and behavior. Although the course of schizophrenia varies among individuals, it is typically persistent and can be both severe and disabling. Schizophrenia treatment is a lifetime procedure, and the medication used for treating schizophrenia controls the activities of patients.

The rapidly increasing incidence of schizophrenic disorders due to change in lifestyle is among the essential factors that intensify the growth and demand of the schizophrenia drugs market. In addition, the increasing number of senior individuals and the newer drugs and treatments are also being introduced and lifting the market growth. Moreover, the rapid advancements in healthcare and the high demand of sophisticated therapy by physicians and patients will further accelerate the expansion of the schizophrenia drugs market. 

·        The increasing need for better and effective treatment outcomes

The growing concerns associated with the non-adherence to oral schizophrenia medication and the subsequent relapse of symptoms are expected to drive the schizophrenia drugs market growth. This result in the increasing adoption of a form of schizophrenia therapeutic products called the long acting injectable (LAls). In addition, a number of key and recent drug approvals for schizophrenia are of the long acting injectable (LAls) form a number of key market leaders are focusing on the development of this form of schizophrenia drugs. Some of the benefits associated with the LAls include increased stay of the medication in the body and the prevention of non-adherence to drugs by the patients. These schizophrenia drugs are successfully able to reduce the number of relapses which often progresses towards cognitive and irreversible brain damages. Owing to the long acting injectable (LAls) and their high efficacies, the market is anticipated to witness high growth in the near future.

·        Increasing adoption towards the injectable schizophrenia drugs

Injectable-based schizophrenia drugs are one of the most advanced forms of treatment, especially the long acting injectable (LAls). In addition, long acting injectable often help in the eradication of the negatives associated with the oral form of treatment of schizophrenia. Moreover, some of the benefits of the injectable are the adherence to the treatment regimes, the prevention of relapses, and also the irreparable cognitive and neurological damages to the patients. Thus, due to the increasing efficacy and the safety features of these treatment modes, there is a greater adoption and the transitioning towards injectable schizophrenia drugs.

COVID-19 Impact on Schizophrenia Drugs Market

The COVID-19 pandemic has largely impacted globally since December 2019. According to the latest World Health Organization (WHO) report, the US, India, Russia, Brazil, Italy, France, Argentina, Spain, Colombia, the UK, and Mexico are some of the worst affected countries due to the COVID-19. The pandemic is hampering the growth of economies worldwide, and it is likely to continue in 2021. The outbreak of the covid-19 pandemic has both advantages and disadvantages in all the sectors. The outbreak disrupts various industries, such as manufacturing, construction, automotive, textiles, chemicals, cosmetics, tourism, hospitality, consumer goods, transportation, IT and telecom, pharmaceutical, and among others. This results in several obstacles in the supply chain of raw materials required for packaging, resulting in demand-supply gaps. This scenario is expected to a negative impact on the Schizophrenia Drugs market.

With Corona Virus Disease 2019 (COVID-19) pandemic, the world is fighting against Covid-19 pandemic and also economic pandemic, almost impacting trillions of dollars of revenues. Our company brings a high-level insight as well as very deep insights relevant to several promising markets. The study will cover:

·        Rapid shifts in top 100 companies across each sector

·        Growth and decline in each sector due to COVID-19 pandemic

Schizophrenia Drugs Market Strategy

Players operating in the schizophrenia drugs market are mainly focusing on the adoption of various strategies to expand their footprint across the world and taking the initiative for the development of efficient and advanced products.

·        In July 2018, the new antipsychotic drug called Perseris, an extended-release injectable form of risperidone from Indivior PLC won the FDA approval for the treatment of schizophrenia.

·        April 2019: Otsuka Pharmaceutical Co., Ltd. announced the launch of REXULTI tablets for the treatment of schizophrenia in Japan.

Geographical Framework

The schizophrenia drugs market report offers a complete overview of the industry including both qualitative and quantitative information. It offers a complete overview and forecast of the schizophrenia drugs market based on various segments. It also offers market size and forecast estimation from the year 2018 to 2030 with respect to four major regions North America, Europe, Asia-Pacific (APAC), Latin America, Middle East and Africa (LAMEA). The schizophrenia drugs market by each region is further sub-segmented across respective countries and segments. The schizophrenia drugs market report covers a complete analysis and forecast across all regions along with the current trend and opportunities happening in the region.

The report analyzes aspects that are mainly affecting the schizophrenia drugs market from both the demand and supply side and afterward estimates market dynamics affecting the schizophrenia drugs market globally over the forecast period i.e., drivers, restraints, opportunities, and future trends. The schizophrenia drugs market report also offers exhaustive PEST analysis for all four regions namely; North America, Europe, APAC, LAMEA after evaluating political, economic, social, and technological factors affecting the schizophrenia drugs market in these regions. This information can help stakeholders to make appropriate decisions before investing. The schizophrenia drugs market report also describes Porter’s five forces analysis which examines the five forces that make a company competitive while helping identify its strength and weakness. The schizophrenia drugs market analysis will also identify competition, new entrants in the market, supplier power, buyer power, and threat of substitute products and services in the schizophrenia drugs market.


Schizophrenia Drugs Market Insights

The schizophrenia drugs market study offers a complete overview of leading companies and their successful marketing strategies and market contribution, such as business overview, key financial information, SWOT analysis, NOISE analysis, improvement Venn diagram and strategies, such as recent developments, market expansion, partnership, merger & acquisitions, product launch, product update, and other contexts. By examining the data collected from primary and secondary methods, the schizophrenia drugs market report offers actionable insights into future growth based on inputs from industry experts to help readers formulate effective strategies. The schizophrenia drugs market report also covers the investment pocket analysis for various verticals with respect to the market.

Schizophrenia Drugs Market Segmentation


Schizophrenia Drugs Market – by Therapeutic Class

·        Second-Generation Antipsychotics

·        Third-Generation Antipsychotics

·        Others

Schizophrenia Drugs Market – by Treatment

·        Oral

·        Injectable

Schizophrenia Drugs Market – by Geography

·        North America

o   US

o   Canada

o   Mexico

·        Europe

o   Germany

o   France

o   Italy

o   UK

o   Russia

o   Spain

o   Netherlands

o   Rest of Europe

·        Asia-Pacific (APAC)

o   China

o   India

o   South Korea

o   Japan

o   Australia

o   Singapore

o   Rest of APAC

·        LAMEA

o   Latin America

o   Middle East

o   Africa

Key Players

1.      AbbVie Inc.

2.      Alkermes

3.      Allergan

4.      Astellas Pharma Inc

5.      AstraZeneca

6.      Bristol-Myers Squibb

7.      Eli Lilly

8.      Gedeon Richter plc

9.      H. Lundbeck A/S

10.   Johnson & Johnson

11.   Novartis AG

12.   Otsuka Pharmaceuticals

13.   Pfizer

14.   Sumitomo Dainippon Pharma

15.   Vanda Pharmaceuticals

Brand Recall

Brand awareness is the methodology by which customers are able to recall or recognize a brand (unaided/aided) under several different conditions with respect to schizophrenia drugs market. These strategies will help the company to make people more aware of your brand — especially by targeting relevant, high-quality audiences for schizophrenia drugs market.


Key Questions Answered

·        Several players are operating in the schizophrenia drugs market globally. Do you know who is leading the overall Schizophrenia Drugs market, and what strategies have been adopted by them?

·        What are the upcoming trends in the Schizophrenia Drugs market? What impact would these trends make in the coming years for the Schizophrenia Drugs market?

Key Benefits for Stakeholders

·        This study presents the analytical description of the schizophrenia drugs market analysis along with the current trends and future estimations to describe coming up investment pockets

·        The complete Schizophrenia Drugs market opportunity is resolute by knowing profitable trends to gain a stronger foothold

·        The report describes insights associated with key drivers, restraints, and opportunities of the schizophrenia drugs market with thorough impact analysis

·        The current schizophrenia drugs market is quantitatively analyzed from 2018 to 2030 to focus on the monetary ability

·        PEST analysis defines the potency of the consumers and suppliers in the schizophrenia drugs market

·        The Porter’s five forces analysis examines the five forces that makes a company competitive while helping identify its strength and weakness. The analysis will also identify competition, new entrants in the market, supplier power, buyer power, and threat of substitute products and services in the Schizophrenia Drugs market

We also offer customized reports as per the requirement of clients to fulfill special requirements. We also provide regional and country reports as well.


Purchase Options

SHARE THIS ON
PERSONALIZE THIS RESEARCH
Triangulate with your Own Data
Get Data as per your Format and Definition
Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
Any level of Personalization

Related Reports